The Utility of FDG-PET for Radiation Treatment in NSCLC
- Conditions
- Positron Emission TomographyLung Neoplasms
- Registration Number
- NCT00385164
- Lead Sponsor
- AHS Cancer Control Alberta
- Brief Summary
Patients planned for radical radiation for NSCLC will undergo conventional CT stimulation and also PET/CT scans for definition of radiation target volumes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Non-small cell lung cancer to receive radical radiation
Exclusion Criteria
- unable to tolerate PET/CT scan
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does FDG-PET improve radiation target volume definition compared to CT in NSCLC treatment planning?
What biomarkers correlate with FDG-PET metabolic parameters for predicting NSCLC radiation therapy outcomes?
What adverse events are associated with FDG-PET-guided radiation dosing in non-small cell lung cancer?
How do molecular targets like GLUT1 or HIF-1α influence FDG-PET imaging accuracy in NSCLC radiotherapy?
What is the comparative effectiveness of FDG-PET versus MRI/CT fusion for NSCLC radiation field delineation?
Trial Locations
- Locations (1)
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada